Project Grant R21AG101690
- Federal Grant Award Summary The Jackson Laboratory received a $354,000 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded on March 15, 2026, with a completion date of March 14, 2028. The award funds the development of an automatable protocol for creating human induced pluripotent stem cell (iPSC)-derived microglia and their co-culture with primary astrocytes to investigate disease-associated expression quantitative trait loci (eQTLs)....
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded The Jackson Laboratory a Project Grant totaling $716,579 on December 15, 2025, under the Aging Research program (CFDA 93.866) to conduct research on genetic dissection of microglia functions in complement-mediated synapse loss in Alzheimer's disease. The research project, which extends through November 30, 2030, will leverage Jackson Laboratory's specialized expertise in mammalian genetics and genetically engineered...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Jackson Laboratory $486,750 under the Aging Research program (CFDA 93.866) for a two-year project beginning September 1, 2025, and concluding August 31, 2027. This Project Grant funds research investigating the impact of age-related clonal hematopoiesis (CH)—a condition in which blood-forming stem cells accumulate somatic mutations that provide selective growth advantages—on Alzheimer's disease (AD) pathology onset...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant of $1,459,072 on August 1, 2025, under the Aging Research program (CFDA 93.866) to conduct research on Alzheimer's Disease (AD)-related neurological dysfunction. The research will deliver scientific knowledge and methodological innovations focused on understanding how inhibitory interneurons—specifically parvalbumin (PVALB) and somatostatin (SST) cell types—contribute...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $1.08 million Project Grant to The Johns Hopkins University on August 1, 2025, under the Aging Research program (CFDA 93.866) to develop adeno-associated virus (AAV) vectors for selective manipulation of oligodendrocyte precursor cells (OPCs). The two-year project, concluding July 31, 2027, will generate novel OPC-selective AAV vectors and utilize them to investigate whether reactive transformation of OPCs surrounding...
- Federal Project Grant Award Summary Yale University received a $461,146 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded on May 15, 2025, with completion targeted for April 30, 2027. The award funds research investigating the dysregulation of cortical astrocytes in Alzheimer's disease (AD) models. The primary deliverable is novel scientific research employing advanced mesoscopic imaging techniques to longitudinally measure...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded J. David Gladstone Institutes a Project Grant of $790,288 under the Aging Research program (CFDA 93.866), effective February 15, 2026, through November 30, 2030. The primary deliverable is foundational genetic research aimed at identifying disease-driving genetic variants within the MAPT locus on chromosome 17q21.31, a region associated with Alzheimer's disease and related dementias as well as multiple other...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of South Florida $3.297 million under the Aging Research program (CFDA 93.866) for a four-year project period (September 1, 2025 – August 31, 2029) to develop novel peptidomimetic biomaterials that inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The research deliverables include the rational design and characterization of structurally related analogues to a lead compound that stabilizes Aβ...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $284,108 to the Regents of the University of Michigan, with an award date of January 1, 2026 and completion deadline of December 31, 2027, under the Aging Research program (CFDA 93.866). This grant funds research investigating how mechanical changes in the aging brain—specifically decreased stiffness and increased viscoelasticity—affect microglial function and contribute to Alzheimer's disease...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $454,937 Project Grant to The Research Foundation for the State University of New York (Stony Brook University) under the Aging Research program (CFDA 93.866) to conduct research on "Regulatory Landscape of Neurodegeneration by Single-Cell Spatial Multiomics." The award, issued on February 15, 2026, with an ultimate completion date of January 31, 2028, supports investigation into the cellular and molecular...
The National Institute on Aging (NIA) awarded The Jackson Laboratory a $486,750 Project Grant on June 15, 2026, under the Aging Research program (CFDA 93.866) to develop and validate an innovative tri-culture microphysiological system for studying Alzheimer's Disease (AD) pathology. The primary deliverable is a human glial-neuronal platform that integrates neurons, astrocytes, and oligodendrocytes on a microfluidic device to enable axonal maturation, myelination, and synaptic connectivity under physiological conditions. This system will provide unprecedented spatiotemporal resolution for mechanistic studies of axonopathy and myelin degradation—two critical hallmarks of AD pathophysiology—that current in vitro models fail to adequately replicate. The project, which extends through May 31, 2028, addresses a significant gap in AD research by creating a more biologically representative model that captures the complex interactions between multiple brain cell types essential for understanding axonal transport dysfunction and its role in neurodegeneration. The completed system will serve as a foundational research tool to investigate whether axonopathy represents a primary cause, facilitator, or consequence of AD, thereby advancing the scientific understanding necessary for developing targeted therapeutic interventions for age-related neurodegenerative disease.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $486.8k | 6/8/26 |